机构:[1]Department of Oncology, School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China.[2]Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital &四川省肿瘤医院[3] Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.四川省肿瘤医院
This work was supported by the 2021 China International Medical Exchange Young and Middleaged Scholars Special Fund (Grant No. Z-2014-06-2103), the Chinese Thoracic Oncology Group (CTONG) Elite Program Fund (Grant No. YC20210105), and the 2022 CSCO Key Program (Grant No. Y-2021AST/zd-0119).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类|4 区医学
小类|4 区肿瘤学4 区药学
最新[2025]版:
大类|4 区医学
小类|4 区肿瘤学4 区药学
第一作者:
第一作者机构:[1]Department of Oncology, School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China.
通讯作者:
通讯机构:[1]Department of Oncology, School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China.[2]Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital &
推荐引用方式(GB/T 7714):
Yang Fan,Zhao Xing,Xie Hua,et al.Occult epidermal growth factor receptor-mutant lung adenocarcinoma complicated by prostatic metastasis: a case report[J].Anti-Cancer Drugs.2025,doi:10.1097/CAD.0000000000001710.
APA:
Yang Fan,Zhao Xing,Xie Hua,Zhu Yajie,Wang Yi&Zhou Jin.(2025).Occult epidermal growth factor receptor-mutant lung adenocarcinoma complicated by prostatic metastasis: a case report.Anti-Cancer Drugs,,
MLA:
Yang Fan,et al."Occult epidermal growth factor receptor-mutant lung adenocarcinoma complicated by prostatic metastasis: a case report".Anti-Cancer Drugs .(2025)